Answers are grounded in this paper and cite their sources.
This review summarizes available evidence to inform best practices for managing anticoagulation during cardiac rhythm device implantation to balance thromboembolic and bleeding risks.
A substantial proportion of patients who undergo cardiac rhythm device implantation receive anticoagulation to prevent thromboembolism. Many patients have coexisting cardiovascular diseases treated with antiplatelet therapy. Anticoagulation may increase the risk of hemorrhagic complication, while withdrawal of anticoagulation may increase thromboembolic risk. In this article, we review and describe the available evidence, in order to inform best practice .
No takes yet. Share an insight, caveat, or question.
Mangrolia et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: